Cannabinol

Cannabinol (CBN) is one defined chemical compound in the cannabinoid family: CAS 521-35-7, PubChem CID 2543, molecular formula C₂₁H₂₆O₂, an oxygen-containing aromatic cannabinoid of the dibenzopyran class.

It is found in cannabis material, commonly in increasing proportion as delta-9-tetrahydrocannabinol oxidises and aromatises on exposure to air, heat and light. CBN is therefore precisely described as an <strong>oxidative degradation product of THC</strong> and a marker associated with aged cannabis. <strong>It is not oxidised cannabis, and it is not merely &ldquo;old THC&rdquo;.</strong>

<strong>Four labels that are not interchangeable.</strong> <em>Cannabinol</em> is a single compound. <em>Δ9-THC</em> is a different compound with a different formula, retaining a partially hydrogenated ring that CBN's aromatic structure does not. <em>Cannabis</em> is plant material or a statutory material category containing many constituents. <em>Cannabis resin</em> is a separated material, not CBN, not THC and not a synonym for plant material. Singapore lists all four separately, and that is the reason this page exists as its own page: a compound-specific legal entry cannot be answered with a cannabis-material summary.

&ldquo;Sleepy cannabinoid&rdquo; is a marketing nickname, not an established clinical indication.

Cannabinol is a partial agonist at the CB1 cannabinoid receptor with markedly lower affinity and lower efficacy than tetrahydrocannabinol, and comparatively greater relative affinity at CB2, which sits mainly on immune cells rather than on neurons.

The practical result is that it is only weakly psychoactive. Estimates of its potency relative to THC vary between preparations and assays, but every line of evidence puts it well below THC rather than near it.

The widely repeated claim that cannabinol is specifically sedating is not well supported. It is confounded by the fact that CBN-rich material is aged material, which differs from fresh material in many ways at once, and controlled work isolating cannabinol has not reproduced a strong hypnotic effect.

CBN interacts with cannabinoid receptors but is generally less potent at CB1 than Δ9-THC. It may have mild psychoactive effects at sufficient exposure.

Consumer products are often marketed for sleep, yet <strong>the human evidence base is limited and product claims should not be converted into medical conclusions.</strong> Recent controlled preclinical work supports biological activity and sleep effects in animals; that is not a general finding that any given CBN product is an effective or safe sleep medicine.

Because CBN is almost always encountered alongside other cannabinoids in aged plant material, most descriptions of what CBN feels like are descriptions of degraded cannabis rather than of the isolated compound.

Potential harms include drowsiness, impaired attention or coordination, and additive effects with alcohol, sedatives or other cannabinoids.

<strong>Commercial products can contain THC or other cannabinoids even when marketed around CBN</strong>, so legal status, impairment and drug-test risk can depend on the whole product rather than on the named ingredient. For any CBN-labelled product, the named compound and any co-present THC, cannabis material or resin are distinct questions, and only analysis separates them.

Safety data for highly purified CBN and for long-term repeated use remain limited compared with established medicines. The sharpest practical risk is legal: where a jurisdiction names cannabinol as a controlled drug, a product sold as a lawful wellness supplement elsewhere is a controlled-drug offence, and the packaging will not say so.